- CIN
- U24239TG2004PLC043118
- ISIN
- INE0AUR01015
- Incorporated
- 8 Sep 2004
- Registered state
- Telangana
Prices shown are indicative, dealer-quoted and updated periodically — they are not exchange-traded prices and may differ from the price at which a transaction is finally executed.
Business overview
Aurobind Pharma Sciences Limited manufactures oral solid formulations and active pharmaceutical ingredients for regulated and emerging markets, across five plants in Telangana and Himachal Pradesh, three of them US-FDA inspected, with 118 approved filings and exports to 54 countries. The API backward integration covers about 60% of the key starting materials used in its own formulations, which has held gross margin steady through two raw-material spikes. The company is currently at the red-herring-prospectus stage of a proposed public issue, and shares change hands only through negotiated off-market transfers.
Key highlights
- Regulated markets contribute 48% of revenue
- Zero official action indicated at the last three plant inspections
- RHP filed in August 2026; price band expected in the December quarter
- R&D spend held at 6.2% of revenue
Financial snapshot
FY2026 · Audited · Source: Audited annual report
- Revenue FY2026
- ₹5,240.00 Cr
- EBITDA
- ₹1,180.00 Cr
- PAT
- ₹742.00 Cr
- Net worth
- ₹4,860.00 Cr
- Total debt
- ₹1,240.00 Cr
- Cash & equivalents
- ₹680.00 Cr
- Operating cash flow
- ₹894.00 Cr
- EPS
- ₹19.22
Management & board
- NSSince 2009
Nilesh Saxena
Managing Director & CEO
Has led Aurobind Pharma since 2009 and previously held senior operating roles in the same sector.
- RSSince 2012
Rakesh Sinha
Chief Financial Officer
- AKSince 2022
Aditya Kulkarni
Executive Director — Operations
- SSSince 2010
Sanjana Saxena
Company Secretary & Compliance Officer
- SBSince 2010
Sameer Bhatt
Independent Director
Reported financials · FY2024–FY2026
Figures in ₹ crore unless stated. Every column carries its own source and audit status.
| Particulars | FY2026Audited | FY2025Audited | FY2024Audited | YoY |
|---|---|---|---|---|
| Profit & loss | ||||
| Revenue | ₹5,240 Cr | ₹4,610 Cr | ₹4,120 Cr | +13.7% |
| EBITDA | ₹1,180 Cr | ₹968 Cr | ₹812 Cr | +21.9% |
| Profit after tax | ₹742 Cr | ₹592 Cr | ₹468 Cr | +25.3% |
| Earnings per share | ₹19.22 | ₹15.34 | ₹12.12 | — |
| Balance sheet | ||||
| Net worth | ₹4,860 Cr | ₹4,180 Cr | ₹3,660 Cr | +16.3% |
| Total debt | ₹1,240 Cr | ₹1,310 Cr | ₹1,420 Cr | — |
| Cash & equivalents | ₹680 Cr | ₹540 Cr | ₹486 Cr | — |
| Total assets | ₹8,420 Cr | ₹7,640 Cr | ₹6,980 Cr | — |
| Book value per share | ₹126 | ₹108 | ₹94.82 | — |
| Cash flow | ||||
| Operating cash flow | ₹894 Cr | ₹712 Cr | ₹604 Cr | — |
Scroll the table sideways to see all columns
- FY2026 · Audited annual report · period ended 31 Mar 2026 · last updated in the back office 20 Sep 2026
- FY2025 · Audited annual report · period ended 31 Mar 2025
- FY2024 · Audited annual report · period ended 31 Mar 2024
Revenue, EBITDA and PAT
₹ crore. A year with no reported figure is left out rather than drawn as zero.
- Revenue
- EBITDA
- PAT
Every ratio on this tab is derived from the reported figures in the Financials tab and the indicative price in the header — nothing here is a stored value. A ratio that cannot be justified is shown as — with the reason, rather than as a negative or a zero. Ratios move when the indicative price moves.
Size
Balance-sheet items as at FY2026
- Market cap
- ₹32,617 Cr
- Enterprise value
- ₹33,177 Cr
- Indicative price
- ₹845
- Shares outstanding
- 38,60,00,000
Indicative price × shares outstanding
Market cap + debt − cash
Valuation multiples
- P/E
- 44.0x
- P/B
- 6.7x
- EV / EBITDA
- 28.1x
- EPS
- ₹19.22
- Book value / share
- ₹126
- Debt / equity
- 0.3x
On FY2026 PAT
Returns & margins
- ROE
- 15.3%
- ROCE (EBITDA basis)
- 19.3%
- EBITDA margin
- 22.5%
- PAT margin
- 14.2%
- Revenue growth
- 13.7%
- Cash / market cap
- 2.1%
EBITDA ÷ (net worth + debt)
Indicative price snapshots
Each point is a dated dealer-quote average. There is no continuous trading behind these numbers, so no daily series is drawn.
Prices shown are indicative, dealer-quoted and updated periodically — they are not exchange-traded prices and may differ from the price at which a transaction is finally executed.
Snapshot log
| Date | Indicative price | Change | Source |
|---|---|---|---|
| 20 Sep 2026 | ₹845 | -0.58% | Dealer desk average, 7 quotes |
| 20 Aug 2026 | ₹850 | +4.68% | Dealer desk average |
| 20 Jul 2026 | ₹812 | -0.08% | Dealer desk average |
| 20 Jun 2026 | ₹813 | +2.90% | Dealer desk average |
| 20 May 2026 | ₹790 | +1.19% | Dealer desk average |
| 20 Apr 2026 | ₹780 | +1.45% | Dealer desk average |
| 20 Mar 2026 | ₹769 | -0.15% | Dealer desk average |
| 20 Feb 2026 | ₹770 | +1.63% | Dealer desk average |
| 20 Jan 2026 | ₹758 | -1.86% | Dealer desk average |
| 20 Dec 2025 | ₹772 | +0.17% | Dealer desk average |
| 20 Nov 2025 | ₹771 | +1.21% | Dealer desk average |
| 20 Oct 2025 | ₹762 | +1.39% | Dealer desk average |
| 20 Sep 2025 | ₹752 | — | Dealer desk average |
Scroll the table sideways to see all columns
Change is measured against the previous snapshot, not against a calendar period, because snapshots are not collected on a fixed schedule. The header percentages use fixed windows and may not tie exactly to this column.
Corporate actions & events
Dated events sourced from company filings and registrar records.
- Board13 May 2026
Appointment of an independent director
Board strengthened with an additional independent director following a nomination-committee review.
Company filing / RoC
- Bonus4 Apr 2026
Bonus issue in the ratio 1:2
Board approved a bonus issue; record date notified to shareholders on file.
Company filing / RoC
- Dividend15 Mar 2026
Final dividend declared
Dividend recommended by the board, subject to shareholder approval at the AGM.
Company filing / RoC
- Fund raise21 Sep 2025
Preferential allotment to institutional investors
Fresh equity issued to a small group of institutional investors at a board-approved price.
Company filing / RoC
IPO / listing status
- Current stage
- RHP filed
- DRHP filed
- 18 Mar 2026
- RHP filed
- 4 Aug 2026
- Expected window
- Q4 FY2027 (indicative)
- Registrar
- Cygnet Registry Services
- Book-running managers
- Northpoint Capital Advisors, Sterling Securities
Listing timelines are indicative and subject to regulatory approval and market conditions. A filing is not a guarantee of listing.
Lock-in applies after listing
Shares acquired before a public issue are typically subject to a statutory lock-in of six months from the date of listing. Confirm the applicable period before transacting.
Read the lock-in explainerResearch
Information currently unavailable
No research has been published on Aurobind Pharma yet. Sector notes that mention it will appear here when they are.
Documents
Public documents open directly. Private documents are released to verified clients on request.
| Document | Type | FY / date | Source | Access |
|---|---|---|---|---|
| Red Herring Prospectus18.4 MB | RHP | 2026 | Regulator filing | Download |
| Annual Report FY20264.2 MB | Annual report | FY2026 | Company | Download |
| Annual Report FY20253.8 MB | Annual report | FY2025 | Company | Download |
| Audited financial statements — three-year summary620 KB | Financials | FY2024–FY2026 | Statutory filings | Download |
| Investor presentation9.1 MB | Presentation | 2026-07-15 | Company | On request |
Scroll the table sideways to see all columns
Risk assessment
Our own reading of the disclosed information. Treat the levels as judgement, not as fact.
Regulatory inspection
HighAn adverse observation at a plant would stop supply to the largest market.
Pricing pressure
MediumGeneric price erosion in the US continues in the mid single digits.
Listing execution
LowRHP is filed; timeline risk is now narrow.
Risks common to every unlisted holding. You may not find a buyer when you want one, at any price. A listing may be delayed indefinitely or may never happen, and shares can list below the price at which they changed hands in the unlisted market. Disclosure by unlisted companies is thinner than by listed ones, and the indicative price is based on infrequent dealer quotes rather than continuous trading.